Logo

RxGen Gets $1.1M SBIR Grant to Study Genomic Markers of Parkinson s Disease

Dec 08, 2004

NEW YORK, Dec. 8 (GenomeWeb News) - RxGen has received a $1.1 million Fast Track SBIR grant to identify genomic markers of Parkinson's disease.

 

The New Haven, Conn.-based firm will use its PrimaTox predictive toxicology technology program to study toxins such as rotenone, tetrahydroisoquinolone, dithiocarbamate, and Paraquat, which have been implicated as possible environmental causes of Parkinson's disease.

 

RxGen said it would profile in vivo brain RNA expression patterns following exposure to the toxins in an attempt to uncover critical pathways of injury and neuroprotection specific to dopaminergic neurons.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.